Videos

Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the second-line setting.

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its FDA approval for this specific population.

Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 and PIK3CA mutations.

Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering patient-specific factors.

Panelists discuss how testing for specific changes in cancer cells, like ESR1 mutations, can help guide treatment choices for patients with hormone receptor-positive metastatic breast cancer.

Panelists discuss how differentiating primary from secondary erythrocytosis is crucial in guiding treatment strategies, emphasizing the importance of addressing underlying causes such as chronic hypoxia, tumors, or anabolic steroid use while managing hematologic parameters as necessary.

Panelists discuss how belumosudil is particularly effective for patients with lung involvement due to its antifibrotic mechanism.

Panelists discuss how the future of polycythemia vera (PV) management will be shaped by advancements in targeted therapies, precision medicine, and symptom control, with innovations such as next-generation JAK inhibitors, hepcidin mimetics like rusfertide, gene therapies, and personalized treatment approaches offering more effective, tailored, and holistic management options that improve disease control and quality of life for patients.

Panelists discuss how hepcidin mimetics like rusfertide complement existing therapies in polycythemia vera (PV) by regulating iron metabolism, reducing iron overload, and balancing erythropoiesis, which can enhance the effectiveness of cytoreductive treatments, alleviate symptoms like fatigue and splenomegaly, and improve quality of life, particularly in patients with refractory disease or those requiring frequent phlebotomy.

Panelists discuss how clinicians typically taper steroids slowly after starting second-line agents for chronic graft-vs-host disease (cGVHD).

At ASCO 2025, Suneel Kamath, MD, presented an analysis of federal cancer research funding disparities and their ripple effects on care delivery and outcomes.

Erin Cobain, MD, discusses findings from a study exploring the differences in diagnosis and treatment of high-risk breast cancer in Black and White patients.

Naomi Haas, MD, discusses the 5-year follow-up of the KEYNOTE-564 study being presented at the 2025 ASCO Annual Meeting.

Sara M. Tolaney, MD, MPH, shares new data from the ASCENT-04 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer.

Ibrahim Aldoss, MD, discusses a post hoc analysis of ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who did not achieve early MRD negativity.

Christopher Danes, PhD, discusses how patient and caregiver priorities and concerns vary during the course of treatment for non–small cell lung cancer.

Sara M. Tolaney, MD, MPH, highlights a transformative year for breast cancer research at this year’s ASCO Annual Meeting.

Christopher Danes, PhD, discusses a study exploring the differences in priorities for patients and their caregivers when undergoing treatment for non–small cell lung cancer.

Terence M. Williams, MD, PhD, discusses what inspired the new phase 1 DINOMITE trial at City of Hope.

Toon Van Gorp, MD, PhD, discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab soravtansine in patients with folate receptor α–positive, platinum-resistant ovarian cancer.

Ayal Aizer, MD, MHS, discusses the unmet needs in treating patients with brain metastases.

Alexander Kenigsberg, MD, discusses a new option for treating prostate cancer: robotic high-intensity focused ultrasound.

Nini Wu, MD, MBA, highlights key tactics that community oncology practices can implement now to better support their clinicians and staff.

Panelists discuss how the MAJIC-PV trial provides critical evidence that ruxolitinib offers more than symptomatic relief in polycythemia vera, demonstrating approximately 40% reduction in thromboembolic events and improved event-free survival while correlating these clinical benefits with molecular responses through JAK2 V617F allele burden reduction, suggesting ruxolitinib may be truly disease-modifying rather than merely a bandage treatment when comprehensive control of all 3 blood cell lineages (red cells, white cells, and platelets) is achieved.

A panelist discusses how treatment sequencing for neuroendocrine tumors (NETs) is less important than ensuring patients receive all available treatments, highlighting cabozantinib as a reasonable second- or third-line option with manageable adverse effects like hypertension and liver function abnormalities.

A panelist discusses how NCCN guidelines now include cabozantinib as a category 1 recommendation for gastrointestinal (GI) neuroendocrine tumors (NETs) after prior treatment with everolimus or lutetium-177 dotatate, with slightly different recommendations for pancreatic, lung, and thymic NETs.

Panelists discuss how ruxolitinib provides comprehensive benefits for polycythemia vera patients beyond count control, highlighting its remarkable ability to rapidly alleviate severe pruritus (often within 48 hours) and other constitutional symptoms that remain resistant to conventional therapies like hydroxyurea and interferon while also effectively managing cytokine-driven and spleen-related symptoms that significantly impact quality of life.

A panelist discusses how chronic graft-versus-host disease affects 30-70% of allogeneic transplant patients across eight cardinal organs (most commonly skin), presents with varying symptoms from rashes and joint stiffness to dry eyes and lung complications, and requires graded treatment approaches ranging from topical therapies for mild cases to systemic corticosteroids for moderate-to-severe disease, though 50% of patients ultimately need alternative treatments due to steroid dependency or resistance.

Nini Wu, MD, MBA, discusses long-term investments aimed at stabilizing and strengthening the future of community oncology

A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing response rates of almost 50% with 20% complete responses, and offers the advantage of reliable intravenous delivery despite logistical challenges of infusion center visits.